Search - tctmd.com

Displaying 101 - 120 of 162

Sort: Relevancy | Date

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

News Daily News

Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors

September 30, 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

Obesity’s Role in COVID-19 Deaths: ‘Profound’ and Independent of CVD

News Daily News

Obesity’s Role in COVID-19 Deaths: ‘Profound’ and Independent of CVD

August 14, 2020

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

News Daily News

Rosuvastatin-Canagliflozin Combo May Be Toxic, Case Suggests

August 03, 2020

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

News Daily News

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

June 11, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

News Conference News AHA 2019

Dapagliflozin Has Benefits Across Heart Failure Subgroups

November 17, 2019

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

News Daily News

Disparate US Trends in Early CVD Deaths Speak to Need for Targeted Prevention

October 21, 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

Decline in US Deaths From CVD and Diabetes Is Leveling Off

News Daily News

Decline in US Deaths From CVD and Diabetes Is Leveling Off

August 27, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Microvascular Disease Quadruples Risk of Leg Amputation

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

July 08, 2019

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

News Daily News

To Battle CVD in China, the ‘Healthcare Pyramid’ Must Be Flipped

June 25, 2019

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.